Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV

Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting

(2020) Lauren Greenberg et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Dolutegravir Cerebrospinal Fluid Diffusion in HIV-1–Infected Patients with Central Nervous System Impairment

(2019) Thibaut Gelé et al.   Open Forum Infectious Diseases

Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging patients enrolled in the Swiss HIV Cohort Study

(2019) Perrine Courlet et al.   AIDS

Increased dolutegravir peak concentrations in people living with HIV aged 60 and over and analysis of sleep quality and cognition

(2018) Emilie R Elliot et al.   CLINICAL INFECTIOUS DISEASES

SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV

(2018) A Borghetti et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Do people living with HIV experience greater age advancement than their HIV-negative counterparts?

(2018) Davide De Francesco et al.   AIDS

Morning dosing for dolutegravir-related insomnia and sleep disorders

(2017) AF Capetti et al.   HIV MEDICINE

Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid

(2017) Annagloria Palazzo et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

UPLC–MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma

(2017) Marco Simiele et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients

(2016) C Hoffmann et al.   HIV MEDICINE

Development and Validation of a Chromatographic Ultraviolet Method for the Simultaneous Quantification of Dolutegravir and Rilpivirine in Human Plasma

(2016) Valeria Cozzi et al.   THERAPEUTIC DRUG MONITORING

Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients

(2015) Jianping Zhang et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection

(2015) Pauline Bollen et al.   Expert Opinion On Drug Safety

Ageing with HIV: a multidisciplinary review

(2015) A. Calcagno et al.   INFECTION

Dolutegravir – a review of the pharmacology, efficacy, and safety in the treatment of HIV

(2015) Christopher Kandel et al.   Drug Design Development and Therapy